Evidence map›Paper›PMID 22839358›Full record

ArticleJournal of translational medicine2012

Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside.

Beatriz de Melo Maia, André Mourão Lavorato-Rocha, Iara Sant'ana Rodrigues, Glauco Baiocchi, Flávia Munhoz Cestari, Monica Maria Stiepcich, Ludmila Thomé Domingues Chinen, Kátia C Carvalho, Fernando Augusto Soares, Rafael Malagoli Rocha

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Prognostic value of CD117 in cancer: a meta-analysis.International journal of clinical and experimental pathology · 2014
    Pooled it
  3. Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.International journal of molecular sciences · 2021
    Article
  4. Article
  5. Article
  6. New Directions in Vulvar Cancer Pathology.Current oncology reports · 2019
    Review
  7. Article
  8. Somatic pharmacogenomics of gastrointestinal stromal tumor.Cancer drug resistance (Alhambra, Calif.) · 2019
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Beatriz de Melo MaiaAnatomic Pathology Department, Hospital AC Camargo, Rua Antônio Prudente, 109, 1o Andar-Patologia Investigativa, Liberdade, São Paulo, SP, CEP: 01509-900, Brazil. beatriz.melomaia@gmail.com
André Mourão Lavorato-Rocha
Iara Sant'ana Rodrigues
Glauco Baiocchi
Flávia Munhoz Cestari
Monica Maria Stiepcich
Ludmila Thomé Domingues Chinen
Kátia C Carvalho
Fernando Augusto Soares
Rafael Malagoli Rocha
AC Camargo Hospital · BRFleury S.A. (Brazil) · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVulvar carcinomas are rare tumors, and there is limited data regarding molecular alterations. To our knowledge there are no published studies on c-KIT and squamous cell carcinomas of the vulva (VSCC). Although there are a significant number of other tumor types which express c-KIT, there remains controversy as to its relationship to patient outcome. Thus, we wished to investigate such controversial findings to determine the prognostic importance of c-KIT by evaluating its protein and mRNA expression in VSCCs, correlating these findings with clinicopathological features and Human Papillomavirus (HPV) infection.

methodsc-KIT expression was scored by immunohistochemistry (IHC) as positive or negative in 139 formalin-fixed paraffin-embedded (FFPE) cases of vulvar carcinomas arrayed in a tissue microarray (TMA) using the DAKO A4502 rabbit polyclonal c-KIT antibody (diluted 1:100). c-KIT mRNA was evaluated by qRT-PCR in 34 frozen samples from AC Camargo Hospital Biobank (17 tumoral and 17 non-tumoral samples) using TaqMan probes-Applied Biosystems [Hs00174029_m1]. HPV genotyping was assessed in 103 samples using Linear Array® HPV Genotyping Test kit (Roche Molecular Diagnostics, Basel, Switzerland). All results obtained were correlated with clinical and pathological data of the patients.

resultsc-KIT protein was positive by immunohistochemistry in 70.5% of the cases and this was associated with a higher global survival (p = 0.007), a higher recurrence-free survival (p < 0.0001), an absence of associated lesions (p = 0.001), lymph node metastasis (p = 0.0053), and HPV infection (p = 0.034). Furthermore, c-KIT mRNA quantitation revealed higher levels of transcripts in normal samples compared to tumor samples (p = 0,0009).

conclusionsOur findings indicate that those vulvar tumors staining positively for c-KIT present better prognosis. Thus, positivity of c-KIT as evaluated by IHC may be a good predictor for use of more conservative surgery techniques and lymph node dissection in vulvar cancer. So part of the essence of our study is to see the possibility of translating our current results from the bench to the bedside. This will help provide patients a more appropriate, less mutilating treatment, in order to keep the maximum physical and psychic quality as possible to these women.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleHumansImmunohistochemistryMiddle AgedPrognosisProto-Oncogene Proteins c-kitReverse Transcriptase Polymerase Chain ReactionRNA, MessengerVulvar NeoplasmsYoung AdultProto-Oncogene Proteins c-kitRNA, Messenger

Identifiers

PMID22839358
PMCPMC3478999
OpenAlexW2163259212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.